Skip to main content
. 2016 Sep 14;7(45):72819–72832. doi: 10.18632/oncotarget.12022

Table 3. Univariate and multivariate analysis of prognostic factors in the entire patient cohort (n = 141).

Univariate Multivariate
p-value HR 95% CI p-value
Lower Upper
OS
CA9 (Low vs High) 0.229 1.207 0.720 2.022 0.475
CD31 (Low vs High) 0.285 0.956 0.583 1.569 0.860
CD68 (Low vs High) 0.623 1.032 0.860 1.237 0.738
CD20 (Low vs High) 0.864 1.048 0.637 1.724 0.854
Age (< median(65) vs ≥ median) 0488 1.180 0.702 1.985 0.532
Sex (male vs female) 0.291 1.176 0.722 1.917 0.514
Tumour localisation (head vs other) 0.204 0.633 0.279 1.436 0.274
pT-stage (pT1-2 vs pT3-4) 0.001 0.495 0.295 0.829 0.008
pN-stage (pN0 vs pN+) 0.001 1.874 0.927 3.786 0.080
Grading (G1 vs G2 vs G3) 0.056 1.252 0.815 1.926 0.305
Resection margins (R0 vs R1) 0.001 1.374 0.769 2.453 0.283
Type of surgery (W vs PP vs TP) 0762 1.170 0.745 1.839 0.496
PNI (no vs yes) 0.001 1.695 0.977 2.941 0.060
VI (no vs yes) 0.010 1.633 0.883 3.023 0.118
LI (no vs yes) 0.11 0.923 0.516 1.650 0.787
Chemotherapy (no vs 1-2 cycles vs ≥ 3 cycles) < 0.001 0.564 0.406 0.782 0.001
PFS
CA9 (Low vs High) 0.388 1.100 0.680 1.780 0.697
CD31 (Low vs High) 0.349 0.894 0.569 1.406 0.628
CD68 (Low vs High) 0.745 1.010 0.849 1.202 0.908
CD20 (Low vs High) 0.623 0.912 0.586 1.419 0.683
Age (< median(65) vs ≥ median) 0.532 1.168 0.713 1.914 0.538
Sex (male vs female) 0.790 1.041 0.661 1.638 0.864
Tumour localisation (head vs other) 0.204 0.700 0.343 1.429 0.327
pT-stage (pT1-2 vs pT3-4) 0.002 0.557 0.350 0.887 0.014
pN-stage (pN0 vs pN+) 0.001 2.537 1.309 4.916 0.006
Grading (G1 vs G2 vs G3) 0.009 1.476 0.991 2.197 0.055
Resection margins (R0 vs R1) 0.001 1.354 0.798 2.300 0.261
Type of surgery (W vs PP vs TP) 0.704 1.022 0.691 1.510 0.915
PNI (no vs yes) < 0.001 1.878 1.111 3.177 0.019
VI (no vs yes) 0.007 1.473 0.854 2.542 0.164
LI (no vs yes) 0.077 0.961 0.576 1.605 0.880
Chemotherapy (no vs 1-2 cycles vs ≥ 3 cycles) < 0.001 0.692 0.509 0.941 0.019
LPFS
CA9 (Low vs High) 0.375 1.130 0.682 1.874 0.634
CD31 (Low vs High) 0.252 1.015 0.630 1.636 0.950
CD68 (Low vs High) 0.446 1.046 0.874 1.252 0.625
CD20 (Low vs High) 0.850 1.011 0.631 1.622 0.962
Age (< median(65) vs ≥ median) 0.222 1.414 0.845 2.367 0.187
Sex (male vs female) 0.435 1.276 0.805 2.021 0.299
Tumour localisation (head vs other) 0.186 0.689 0.318 1.494 0.345
pT-stage (pT1-2 vs pT3-4) 0.007 0.612 0.375 1.000 0.050
pN-stage (pN0 vs pN+) 0.001 1.930 0.980 3.799 0.057
Grading (G1 vs G2 vs G3) 0.064 1.241 0.824 1.868 0.301
Resection margins (R0 vs R1) 0.001 1.496 0.858 2.609 0.156
Type of surgery (W vs PP vs TP) 0.814 1.056 0.687 1.624 0.804
PNI (no vs yes) < 0.001 1.960 1.139 3.374 0.015
VI (no vs yes) 0.008 1.543 0.851 2.796 0.153
LI (no vs yes) 0.011 0.937 0.541 1.622 0.816
Chemotherapy (no vs 1-2 cycles vs ≥ 3 cycles) < 0.001 0.606 0.442 0.830 0.002
DMFS
CA9 (Low vs High) 0.405 1.189 0.728 1.944 0.489
CD31 (Low vs High) 0.342 0.880 0.550 1.408 0.594
CD68 (Low vs High) 0.949 0.965 0.810 1.150 0.688
CD20 (Low vs High) 0.526 0.848 0.536 1.341 0.481
Age (< median(65) vs ≥ median) 0.818 1.042 0.628 1.729 0.874
Sex (male vs female) 0.452 1.119 0.701 1.786 0.637
Tumour localisation (head vs other) 0.291 0.674 0.318 1.428 0.303
pT-stage (pT1-2 vs pT3-4) 0.001 0.409 0.250 0.671 0.001
pN-stage (pN0 vs pN+) 0.001 2.347 1.197 4.600 0.013
Grading (G1 vs G2 vs G3) 0.004 1.485 0.982 2.243 0.061
Resection margins (R0 vs R1) 0.001 1.351 0.779 2.342 0.284
Type of surgery (W vs PP vs TP) 0.428 1.010 0.666 1.530 0.963
PNI (no vs yes) 0.001 1.590 0.926 2.730 0.093
VI (no vs yes) 0.005 1.640 0.933 2.882 0.086
LI (no vs yes) 0.078 0.963 0.568 1.634 0.890
Chemotherapy (no vs 1-2 cycles vs ≥ 3 cycles) < 0.001 0.706 0.510 0.976 0.035

Abbreviations: HR. hazard ratio; CI, confidence interval; W, Whipples; PP, partial pancreatectomy; TP, total pancreatectomy; VI, vascular invasion; LI, lymphatic invasion; PNI, perineural/neural invasion; OS, overall survival; PFS, progression-free survival; LFFS, local failure-free survival; DMFS, distant metastases-free survival;

Significant values have been marked with bold.